These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 33839046)

  • 1. Antifibrotics in systemic sclerosis.
    Martin-Lopez M; Carreira PE
    Best Pract Res Clin Rheumatol; 2021 Sep; 35(3):101671. PubMed ID: 33839046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease.
    Yamasaki Y; Kuwana M
    Expert Rev Clin Immunol; 2020 Jun; 16(6):547-560. PubMed ID: 32506975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of antifibrotic therapies in the treatment of systemic sclerosis-associated interstitial lung disease.
    Boleto G; Avouac J; Allanore Y
    Ther Adv Musculoskelet Dis; 2022; 14():1759720X211066686. PubMed ID: 35111241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should we use nintedanib as early therapy in patients with SSc-ILD?
    Zanatta E; Moccaldi B; Szucs G; Spagnolo P
    Autoimmun Rev; 2024 Jan; 23(1):103463. PubMed ID: 37844857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Modern drug therapy for systemic sclerosis associated interstitial lung disease].
    Aringer M; Koschel D; Krause A; Schneider U; Gläser S
    Dtsch Med Wochenschr; 2022 Feb; 147(4):179-186. PubMed ID: 34861699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic sclerosis with associated interstitial lung disease: management considerations and future directions.
    Bernstein EJ; Huggins JT; Hummers LK; Owens GM
    Am J Manag Care; 2021 May; 27(7 Suppl):S138-S146. PubMed ID: 34003617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological treatment of systemic sclerosis-associated interstitial lung disease: an updated review and current approach to patient care.
    Mendoza FA; Allawh T; Jimenez SA
    Clin Exp Rheumatol; 2023 Aug; 41(8):1704-1712. PubMed ID: 37382458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expert consensus on the management of systemic sclerosis-associated interstitial lung disease.
    Rahaghi FF; Hsu VM; Kaner RJ; Mayes MD; Rosas IO; Saggar R; Steen VD; Strek ME; Bernstein EJ; Bhatt N; Castelino FV; Chung L; Domsic RT; Flaherty KR; Gupta N; Kahaleh B; Martinez FJ; Morrow LE; Moua T; Patel N; Shlobin OA; Southern BD; Volkmann ER; Khanna D
    Respir Res; 2023 Jan; 24(1):6. PubMed ID: 36624431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of systemic sclerosis-associated interstitial lung disease.
    Roofeh D; Jaafar S; Vummidi D; Khanna D
    Curr Opin Rheumatol; 2019 May; 31(3):241-249. PubMed ID: 30870216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current advances in the treatment of systemic sclerosis.
    Bukiri H; Volkmann ER
    Curr Opin Pharmacol; 2022 Jun; 64():102211. PubMed ID: 35447517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological treatments for SSc-ILD: Systematic review and critical appraisal of the evidence.
    Vonk MC; Smith V; Sfikakis PP; Cutolo M; Del Galdo F; Seibold JR
    Autoimmun Rev; 2021 Dec; 20(12):102978. PubMed ID: 34718159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interstitial Lung Disease: How Should Therapeutics Be Implemented?
    Bruni C; Campochiaro C; de Vries-Bouwstra JK
    Rheum Dis Clin North Am; 2023 May; 49(2):279-293. PubMed ID: 37028835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of systemic sclerosis: the first five years.
    Roofeh D; Khanna D
    Curr Opin Rheumatol; 2020 May; 32(3):228-237. PubMed ID: 32205570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nintedanib downregulates the profibrotic M2 phenotype in cultured monocyte-derived macrophages obtained from systemic sclerosis patients affected by interstitial lung disease.
    Soldano S; Smith V; Montagna P; Gotelli E; Campitiello R; Pizzorni C; Paolino S; Sulli A; Cere A; Cutolo M
    Arthritis Res Ther; 2024 Mar; 26(1):74. PubMed ID: 38509595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and Emerging Drug Therapies for Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD).
    Jee AS; Corte TJ
    Drugs; 2019 Sep; 79(14):1511-1528. PubMed ID: 31399860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [How do I treat interstitial lung disease in systemic sclerosis?].
    Riemekasten G
    Z Rheumatol; 2021 Feb; 80(1):69-72. PubMed ID: 33340058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
    Barnes H; Holland AE; Westall GP; Goh NS; Glaspole IN
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD010908. PubMed ID: 29297205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Importance of mycophenolate mofetil for treatment of interstitial lung disease in systemic sclerosis].
    Schneider U; Siegert E; Gläser S; Krüger K; ; Krause A
    Z Rheumatol; 2021 Nov; 80(9):868-878. PubMed ID: 34545432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interstitial Lung Disease Associated with Systemic Sclerosis.
    Mismetti V; Si-Mohamed S; Cottin V
    Semin Respir Crit Care Med; 2024 Jun; 45(3):342-364. PubMed ID: 38714203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of interstitial lung disease in systemic sclerosis: lessons from SLS and FAST.
    Fathi N; Furst DE; Clements PJ
    Curr Rheumatol Rep; 2007 May; 9(2):144-50. PubMed ID: 17502045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.